Latest research on Dexmethylphenidate

Dexmethylphenidate is the dextrorotary form of methylphenidate. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Dexmethylphenidate indications

Dexmethylphenidate (d-MPH) hydrochloride is a D-threo enantiomer of racemic D,L-methylphenidate with an approximately tenfold greater potent pharmacological effect than L-methylphenidate. [source, 2015]
Dexmethylphenidate (the threo-(R,R)-isomer of methylphenidate) has been extensively shown to be wholly responsible for the DAT-mediated physiological effects of the racemate [63], [64] and was therefore selected for modeling. [source, 2011]
The 6-month, open-label follow-up trial primarily evaluated the safety effects of patients taking Dexmethylphenidate for an extended period of time. [source, 2010]
In summary, the positive treatment effect of Dexmethylphenidate from the double-blinded phase was maintained throughout the 6 months. [source, 2010]
MPH and Dexmethylphenidate have proven to be effective on all ADHD symptoms, including inattentive and hyperactive/impulsive symptoms. [source, 2010]
It is important for clinicians to understand that treatment effects with MPH and Dexmethylphenidate can be seen as early as the first week of treatment. [source, 2010]
In Switzerland Dexmethylphenidate XR was licensed for use in adults in 2009 and this has been reported as a safe and effective option [292]. [source, 2010]